NASDAQ:KRBP - Nasdaq - US4976342042 - Common Stock - Currency: USD
1.45
-0.13 (-8.23%)
The current stock price of KRBP is 1.45 USD. In the past month the price decreased by -38.56%. In the past year, price decreased by -86.7%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Kiromic Biopharma, Inc. operates as a clinical-stage biotherapeutics company. The company is headquartered in Houston, Texas and currently employs 31 full-time employees. The company went IPO on 2020-10-16. The firm is engaged in developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The Procel, Isocel, and Deltacel product platform candidates consist of allogeneic cell therapy candidates that are in the preclinical development stage. Its Procel product candidate consists of engineered GDTs targeting PD-L1. Its Isocel product candidate consists of engineered GDTs targeting Mesothelin Isoform 2 positive tumors (Iso-Meso). Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. Its Allogenic Lead Exogenous Isoforms (ALEXIS)-PRO-1 trial candidate is its allogeneic GDT therapy product targeting PD-L1. Its ALEXIS-ISO-1 trial candidate is its allogenic GDT therapy product targeting an isoform of Mesothelin that is present in tumor cells, namely Isomeso.
KIROMIC BIOPHARMA INC
7707 Fannin St., Suite 140
Houston TEXAS 77054 US
CEO: Maurizio Chiriva-Internati
Employees: 31
Company Website: https://kiromic.com/
Phone: 18329684888.0
The current stock price of KRBP is 1.45 USD. The price decreased by -8.23% in the last trading session.
The exchange symbol of KIROMIC BIOPHARMA INC is KRBP and it is listed on the Nasdaq exchange.
KRBP stock is listed on the Nasdaq exchange.
KIROMIC BIOPHARMA INC (KRBP) has a market capitalization of 1.71M USD. This makes KRBP a Nano Cap stock.
KIROMIC BIOPHARMA INC (KRBP) currently has 31 employees.
KIROMIC BIOPHARMA INC (KRBP) has a resistance level at 2.83. Check the full technical report for a detailed analysis of KRBP support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
KRBP does not pay a dividend.
KIROMIC BIOPHARMA INC (KRBP) will report earnings on 2023-11-13, after the market close.
KIROMIC BIOPHARMA INC (KRBP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-47.46).
The outstanding short interest for KIROMIC BIOPHARMA INC (KRBP) is 0.09% of its float. Check the ownership tab for more information on the KRBP short interest.
Over the last trailing twelve months KRBP reported a non-GAAP Earnings per Share(EPS) of -47.46. The EPS increased by 24.87% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | N/A |